NCT06978192 Clinical Study on the Treatment of Herpes Zoster Pain With Dexmedetomidine Combined With Long-term High Voltage
| NCT ID | NCT06978192 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Fenghui Deng |
| Condition | Herpes Zoster (HZ) |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 92 participants in total. It began in 2024-12-16 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Participants will be invited to take part in clinical research. This informed consent form will provide information to the participants to help them decide whether to participate in the clinical study. If participants have any questions, please ask them directly to the researcher in charge of this study. This study was approved by the Biomedical Research Ethics Review Committee of the Institute. This trial is a randomized controlled clinical study. According to the different treatment methods, the control group was randomly divided into the control group and the experimental group. Control group: On the basis of conventional drug treatment, long-term high-voltage pulsed radiofrequency treatment was carried out. Experimental group: On the basis of conventional drug treatment, dexmedetomidine nasal spray was administered before HL-PRF treatment, before bedtime on the day of the operation, and before bedtime on the 1st to 3rd days after the operation. Heart rate, blood pressure and blood oxygen saturation were monitored respectively before the operation, during the operation and after the operation. Telephone follow-ups were conducted at 1 week, 1 month, 3 months and 6 months after the operation respectively. If the participants agree to participate in this study, the researchers will number the participants and establish medical records. The researchers will have detailed communication with the participants or their families, inform them of the research situation, and ask the participants to provide disease information, including the onset of the disease, family history, previous medical visits and some examination results. What do you need to do in this research? Once participating in the study, participants will be required to provide true information about their medical history and current physical condition. Tell the research doctor about any discomfort you encountered during the research process; Do not take restricted drugs, foods, etc. Tell the research doctor whether you have participated in or are currently participating in any other research recently. Risks and discomfort: Communicating and talking with researchers may cause participants to feel psychologically uncomfortable. Since this study only collected the medical history, data and epidemiological investigation of patients or normal people, there is no harm in this study. If participants are injured during the clinical trial, they can receive free treatment and/or appropriate compensation in accordance with Chinese law. What are the benefits of participating in this research? Useful information can be provided for disease research by studying the information of the participants. The cost of participating in this study: Participation in this study will be based on the medical information of the research participants, and the related costs will not be borne by the participants. Privacy issue: If participants decide to take part in this study, their participation status and personal data during the study period will be kept confidential. When necessary, government administrative departments or members of the ethics review committee may access the personal data of participants in research institutions. When the results of this study are announced, the personal identity information of the participants will not be disclosed.
Eligibility Criteria
Inclusion Criteria: * Patients with adverse reactions that are not effective in conventional drug treatment and cannot tolerate drugs * The pain is located in the corresponding innervated are * The pain affects the patient's daily life or work * Diagnostic nerve block is effective and pain limited * Recurrent herpes zoster pain * Patients with shingle-related pain aged 40-85 years Exclusion Criteria: * Infection at the puncture site, systemic infection that may spread, and malignant tumors near the puncture * There are contraindications in minimally invasive interventional therapy such as coagulation function and platelet dysfunction * Allergies to local anesthetics and inhalants * Heart, lung, liver, kidney and other important organ failure, can not tolerate surgery * Severe endocrine system diseases or long-term use of hormone or immunosuppressive therapy * Patients with cardiac pacemakers, pregnant or lactating women * Patients with cognitive dysfunction or poor coordination * Patients who have been treated with electrical stimulation or PRF
Contact & Investigator
Deng
PRINCIPAL INVESTIGATOR
Fenghui
Frequently Asked Questions
Who can join the NCT06978192 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Herpes Zoster (HZ). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06978192 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06978192 currently recruiting?
Yes, NCT06978192 is actively recruiting participants. Contact the research team at 254670750@qq.com for enrollment information.
Where is the NCT06978192 trial being conducted?
This trial is being conducted at Zunyi, China.
Who is sponsoring the NCT06978192 clinical trial?
NCT06978192 is sponsored by Fenghui Deng. The principal investigator is Deng at Fenghui. The trial plans to enroll 92 participants.